RU2019105574A - Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор - Google Patents

Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор Download PDF

Info

Publication number
RU2019105574A
RU2019105574A RU2019105574A RU2019105574A RU2019105574A RU 2019105574 A RU2019105574 A RU 2019105574A RU 2019105574 A RU2019105574 A RU 2019105574A RU 2019105574 A RU2019105574 A RU 2019105574A RU 2019105574 A RU2019105574 A RU 2019105574A
Authority
RU
Russia
Prior art keywords
paclitaxel
tumor
amount
day
arabinofuranosyl
Prior art date
Application number
RU2019105574A
Other languages
English (en)
Other versions
RU2019105574A3 (ru
RU2752172C2 (ru
Inventor
Ёсихиде ИВАКИ
Цукаса КИТАХАСИ
Синдзи МИМА
Original Assignee
Фуджифилм Корпорэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фуджифилм Корпорэйшн filed Critical Фуджифилм Корпорэйшн
Publication of RU2019105574A3 publication Critical patent/RU2019105574A3/ru
Publication of RU2019105574A publication Critical patent/RU2019105574A/ru
Application granted granted Critical
Publication of RU2752172C2 publication Critical patent/RU2752172C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Claims (7)

1. Противоопухолевый агент, содержащий паклитаксел в количестве 1~1000 мг/м2/день; и 1-(2-дезокси-2-фтор-4-тио-β-D-арабинофуранозил)цитозина метансульфонат в количестве 1~2000 мг/м2/день.
2. Противоопухолевый агент по п. 1, где применяемое количество 1-(2-дезокси-2-фтор-4-тио-β-D-арабинофуранозил)цитозина метансульфоната равно 0,01-100-кратному молярному количеству паклитаксела.
3. Противоопухолевый агент по п. 1 или 2, где противоопухолевый агент предназначен для рака поджелудочной железы.
4. Противоопухолевый агент по любому из пп. 1-3, где паклитакселом является наночастица, содержащая паклитаксел и альбумин.
5. Противоопухолевый агент по любому из пп. 1-4, где паклитакселом является наб-паклитаксел.
6. Усилитель противоопухолевого действия, содержащий 1-(2-дезокси-2-фтор-4-тио-β-D-арабинофуранозил)цитозина метансульфонат в количестве 1~2000 мг/м2/день.
7. Противоопухолевый набор, содержащий препарат, содержащий паклитаксел в количестве 1~1000мг/м2/день; ипрепарат, содержащий 1-(2-дезокси-2-фтор-4-тио-β-D-арабинофуранозил)цитозина метансульфонат в количестве 1~2000 мг/м2/день.
RU2019105574A 2016-08-31 2017-08-30 Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор RU2752172C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-169167 2016-08-31
JP2016169167 2016-08-31
PCT/JP2017/031074 WO2018043530A1 (ja) 2016-08-31 2017-08-30 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット

Publications (3)

Publication Number Publication Date
RU2019105574A3 RU2019105574A3 (ru) 2020-10-01
RU2019105574A true RU2019105574A (ru) 2020-10-01
RU2752172C2 RU2752172C2 (ru) 2021-07-23

Family

ID=61301073

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019105574A RU2752172C2 (ru) 2016-08-31 2017-08-30 Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор

Country Status (14)

Country Link
US (1) US11369625B2 (ru)
EP (1) EP3508205B1 (ru)
JP (2) JP7008025B2 (ru)
KR (1) KR102198656B1 (ru)
CN (1) CN109641009B (ru)
AU (1) AU2017319260B2 (ru)
BR (1) BR112019003946A2 (ru)
CA (1) CA3035334C (ru)
MX (1) MX2019002430A (ru)
RU (1) RU2752172C2 (ru)
SG (1) SG11201901815WA (ru)
TW (1) TWI787201B (ru)
WO (1) WO2018043530A1 (ru)
ZA (1) ZA201901563B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
TW202002988A (zh) * 2018-03-13 2020-01-16 日商富士軟片股份有限公司 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用試劑盒
WO2019176984A1 (ja) * 2018-03-13 2019-09-19 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2023008511A1 (ja) 2021-07-29 2023-02-02 富士フイルム株式会社 Ｂａｐ１およびｐｂｒｍ１の少なくとも１つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US3243425A (en) 1962-10-29 1966-03-29 Purdue Research Foundation Novel sulfur-containing compounds
JPS53119810A (en) 1977-03-25 1978-10-19 Mitsubishi Chem Ind Ltd Preparation of aldehyde chloride
US4211773A (en) 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4220774A (en) 1978-10-26 1980-09-02 Omnium Chimique Vincadifformine synthesis process
JPS5692239A (en) 1979-12-27 1981-07-25 Sagami Chem Res Center Preparation of 5-oxohexyl compound
US4803272A (en) 1987-02-24 1989-02-07 E. I. Du Pont De Nemours And Company S-modified adenosyl-1,8-diamino-3-thiooctane derivatives
IE74701B1 (en) 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
JP3138834B2 (ja) 1991-12-26 2001-02-26 生化学工業株式会社 フコピラノース類縁体の製造方法およびその合成中間化合物
GB9218810D0 (en) 1992-09-04 1992-10-21 Univ Birmingham Antiviral pyrimidine nucleosides
WO1996001834A1 (fr) 1994-07-12 1996-01-25 Yamasa Corporation 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside
JPH0853490A (ja) 1994-08-09 1996-02-27 Yamasa Shoyu Co Ltd ２’−デオキシ−２’，２’−ジハロゲノ−４’−チオヌクレオシド
JP4202327B2 (ja) 1996-04-09 2008-12-24 ヤマサ醤油株式会社 １−（２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノシル）シトシン
WO1997037993A1 (fr) 1996-04-09 1997-10-16 Yamasa Corporation DERIVES DE 9-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)PURINE
WO1997038001A1 (fr) * 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES
US7875733B2 (en) 2003-09-18 2011-01-25 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
HUP9601756A3 (en) 1996-06-25 1999-05-28 Richter Gedeon Vegyeszet New anticoagulant glycosides and pharmaceutical compositions containing them
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
JP4087471B2 (ja) 1997-03-31 2008-05-21 大日本印刷株式会社 表面プラズモン共鳴バイオセンサー用測定チップ及びその製造方法
HUP9702348A3 (en) 1997-12-04 2000-12-28 Richter Gedeon Vegyeszet New anticoagulant glycosides and pharmaceutical conew anticoagulant glycosides and pharmaceutical compositions containing them mpositions containing them
WO1999043690A1 (fr) 1998-02-25 1999-09-02 Rational Drug Design Laboratories Compose de l-4'-arabinofuranonucleoside et composition medicinale le contenant
ES2376862T3 (es) 1998-07-23 2012-03-20 Southern Research Institute Utilización de compuestos de tioarabinofuranosilo
AU2001240098A1 (en) 2000-03-08 2001-09-17 Southern Research Institute 4'-thio-l-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof
KR100426030B1 (ko) 2000-07-22 2004-04-03 (주) 한켐 락톤계 당화합물에서의 키랄성 전환방법
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
EE200300429A (et) 2001-03-06 2003-12-15 Bristol-Myers Squibb Company Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks
BR0210594A (pt) 2001-06-22 2005-11-01 Pharmasset Ltd (beta)-d ou (beta)-l-3-halonucleosìdeo
JP2003172990A (ja) 2001-08-03 2003-06-20 Fuji Photo Film Co Ltd ハロゲン化銀乳剤及びハロゲン化銀写真感光材料
EP1492523A2 (en) * 2001-11-23 2005-01-05 Chugai Seiyaku Kabushiki Kaisha Method for identification of tumor targeting enzymes
BR0310006A (pt) 2002-08-09 2005-02-15 Taisho Pharmaceutical Co Ltd Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
AU2003200960B2 (en) 2002-09-18 2005-01-06 Mackinnon, Sebastian Mr System for Ordering, Tracking and Payment of Goods and Services
JP2006522163A (ja) * 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用
CA2525099A1 (en) 2003-05-12 2004-11-25 Purdue Research Foundation Cytotoxic indeno and isoindoloisoquinolones
EP1630157A4 (en) 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
JPWO2004106352A1 (ja) 2003-05-29 2006-07-20 大正製薬株式会社 アルドヘキソピラノース中間体の製造法
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
EP2301531B1 (en) 2005-02-18 2018-06-06 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
JP2006335737A (ja) 2005-06-03 2006-12-14 Ihara Nikkei Kagaku Kogyo Kk ベンゾ［ｃ］ヘテロ５員環化合物の製造方法
WO2007056596A2 (en) 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
WO2007068113A1 (en) 2005-12-16 2007-06-21 Mcgill University 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof
CN100513395C (zh) 2006-04-17 2009-07-15 中国科学院化学研究所 一种制备多羟基环状硝酮的方法
JP5320284B2 (ja) 2006-05-03 2013-10-23 キメリクス，インコーポレーテッド 抗ウイルス性または抗増殖性のホスホネート、ヌクレオシドホスホネートおよびヌクレオシドホスフェートの代謝安定性アルコキシアルキルエステル
CN101200463B (zh) 2007-12-11 2011-06-22 复旦大学 全酰化-4-硫代-d-核糖及其制备方法
AU2008335469A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
US8859589B2 (en) 2008-03-12 2014-10-14 Southern Research Institute Use of 4′-thio-2′-deoxynucleosides as anti orthopoxvirus agents
CN101880287B (zh) 2009-05-05 2012-07-25 上海医药工业研究院 一类四氢噻吩核苷类似物的中间体化合物及其制备方法
CN102656154B (zh) 2009-12-18 2014-04-09 天秤医药股份有限公司 用于制备取代的1-O-酰基-2-脱氧-2-氟-4-硫代-β-D-***呋喃糖的方法
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CN102166190B (zh) 2011-04-14 2013-04-10 上海市肺科医院 一种双重靶向肿瘤的紫杉醇纳米脂质体及其制备方法
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
JP5776564B2 (ja) 2012-01-20 2015-09-09 日本精工株式会社 ワーク処理装置、及びワーク処理方法
TWI637963B (zh) * 2012-03-28 2018-10-11 富士軟片股份有限公司 １－（２－脫氧－２－氟－４－硫－β－Ｄ－***呋喃糖基）胞嘧啶之鹽
PT2833905T (pt) * 2012-04-04 2018-08-06 Halozyme Inc Terapia de combinação com hialuronidase e um taxano dirigido a tumor
US20140029864A1 (en) 2012-07-30 2014-01-30 Dror Reif Compression encoding and decoding method and apparatus
ES2733061T3 (es) 2012-08-10 2019-11-27 Taiho Pharmaceutical Co Ltd Dispersión acuosa de liposomas encapsulantes de oxaliplatino estable y método para estabilización de la misma
PL2883866T3 (pl) 2012-08-13 2019-07-31 Fujifilm Corporation Produkt pośredni do syntezy 1-(2-deoksy-2-fluoro-4-tio-beta-d-arabinofuranosylo)cytozyny, produkt pośredni do syntezy tionukleozydu i sposoby otrzymywania tych produktów pośrednich
TW201542581A (zh) 2013-09-11 2015-11-16 Univ Emory 核苷酸與核苷治療組成物及其相關用途
JP6175553B2 (ja) 2014-02-18 2017-08-09 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6204223B2 (ja) 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
CN109553651B (zh) 2015-04-03 2021-08-06 四川科伦博泰生物医药股份有限公司 4’-硫代核苷的新型化合物及其制备方法、药物组合物和应用
US20190381084A1 (en) 2015-12-23 2019-12-19 Nucana Biomed Limited Combination therapy
JP6450356B2 (ja) 2016-02-29 2019-01-09 富士フイルム株式会社 液状医薬製剤
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
WO2019176984A1 (ja) 2018-03-13 2019-09-19 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット

Also Published As

Publication number Publication date
ZA201901563B (en) 2020-09-30
EP3508205A4 (en) 2019-09-04
US11369625B2 (en) 2022-06-28
RU2019105574A3 (ru) 2020-10-01
NZ751051A (en) 2021-09-24
AU2017319260B2 (en) 2020-01-30
MX2019002430A (es) 2019-07-04
WO2018043530A1 (ja) 2018-03-08
KR20190034310A (ko) 2019-04-01
EP3508205B1 (en) 2022-05-18
CN109641009B (zh) 2021-12-31
US20190192546A1 (en) 2019-06-27
JPWO2018043530A1 (ja) 2019-07-04
RU2752172C2 (ru) 2021-07-23
JP7008025B2 (ja) 2022-01-25
AU2017319260A1 (en) 2019-03-21
KR102198656B1 (ko) 2021-01-05
CA3035334A1 (en) 2018-03-08
JP2021014474A (ja) 2021-02-12
SG11201901815WA (en) 2019-04-29
EP3508205A1 (en) 2019-07-10
CA3035334C (en) 2022-05-10
TWI787201B (zh) 2022-12-21
BR112019003946A2 (pt) 2019-05-21
CN109641009A (zh) 2019-04-16
TW201811323A (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
RU2019105574A (ru) Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MA41937B1 (fr) Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
PH12018502606A1 (en) Phosphoramidate nucleoside derivatives as anticancer agents
EA201792169A1 (ru) 5'-замещенные нуклеозидные соединения
MX370662B (es) Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.
EA201890894A1 (ru) Комбинированная терапия
MX2020006010A (es) Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
CY1126037T1 (el) Παραγων κατα των ογκων και ενισχυτης επιδρασεων κατα των ογκων
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
JP2018522053A5 (ru)
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
WO2018054989A9 (en) Benzoimidazole derivatives as anticancer agents
WO2019241644A8 (en) Novel small molecule anticancer agents, combinations and uses thereof
EA201700286A1 (ru) Макромолекулярные комплексы переходного металла для лечения рака и способ их получения
JP2019506382A5 (ru)
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
MX2019008773A (es) Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
JP2017516827A5 (ru)
EA200971103A1 (ru) Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами
JO3630B1 (ar) توليفة أليسيرتيب وباكليتاكسيل لعلاج السرطان